bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure from PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design
Authors: Nag Jeetendra Kumar , Malka Hodaya , Sedley Shoshana , Appasamy Priyanga , Rudina Tatyana , Levi Tgst , Hoffman Amnon , Gilon Chaim , Uziely Beatrice , Bar-Shavit Rachel
Published: April 2023

Supplementary Figure from PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design
Supplementary Data from Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment
Authors: Ning Shu , Liu Chengfei , Lou Wei , Yang Joy C. , Lombard Alan P. , D'Abronzo Leandro S. , Batra Neelu , Yu Ai-Ming , Leslie Amy R. , Sharifi Masuda , Evans Christopher P. , Gao Allen C.
Published: April 2023

Supplementary Data from Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment
Supplementary Data from PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design
Authors: Nag Jeetendra Kumar , Malka Hodaya , Sedley Shoshana , Appasamy Priyanga , Rudina Tatyana , Levi Tgst , Hoffman Amnon , Gilon Chaim , Uziely Beatrice , Bar-Shavit Rachel
Published: April 2023

Supplementary Data from PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design
Supplementary Data from PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors
Authors: Thomas Anish , Fontaine Shaun D. , Diolaiti Morgan E. , Desai Parth , Kumar Rajesh , Takahashi Nobuyuki , Sciuto Linda , Nichols Samantha , Ashworth Alan , Feng Felix Y. , Ashley Gary W. , Nguyen Minh , Pommier Yves , Santi Daniel V.
Published: April 2023

Supplementary Data from PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors
Supplementary Data from Transcription Factor–Forced Astrocytic Differentiation Impairs Human Glioblastoma Growth In Vitro and In Vivo
Authors: Trovato Francesco , Stefani Francesca Romana , Li Jiaxin , Zetterdahl Oskar G. , Canals Isaac , Ahlenius Henrik , Bengzon Johan
Published: April 2023

Supplementary figures and table
Supplementary Data from Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer
Authors: Rodak Magdalena , Dekempeneer Yana , Wojewódzka Maria , Caveliers Vicky , Covens Peter , Miller Brian W. , Sevenois Matthijs B. , Bruchertseifer Frank , Morgenstern Alfred , Lahoutte Tony , D'Huyvetter Matthias , Pruszyński Marek
Published: April 2023

Supplementary Data from Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer
Abstract 6235: Discovery of novel HDAC6 inhibitors that enhance proteasomal activity to boost antigen presentation and trigger anti-myeloma T-cell immunity
Authors: Rana Priyanka S. , Ignatz-Hoover James , Driscoll James J.
Published: April 2023

Transformative success of cancer immunotherapy has revolutionized cancer treatment and can induce long lasting responses in patients with cancers from a wide range of histologies. However, only a fraction of patients respond to immunotherapy and cancer cells escape immunosurveillance through molecular mechanisms that remain elusive. Proteasomes play a central role in the immune response by generating peptides from intracellular antigens which are presented on the cell surface for recognition by CD8+ cytotoxic T lymphocytes (CTLs). Malignant cells employ strategies to downregulate antigen presentation and impair CTL-mediated tumor recognition and lysis. Recently, we discovered that HDAC6-specific inhibitors increased intracellular proteasome activity and the generation of antigenic class I MHC peptides. However, current HDAC6 inhibitors have pharmacologic liabilities that limit efficacy, e.g., low potency and solubility, poor pharmacokinetic properties and potential genotoxicity. Therefore, we performed a cell-based, high-throughput screen (HTS) of 9,600 HDAC-specific compounds to identify novel compounds that increased proteasomal activity in myeloma cells. We identified 8 hits that increased proteasomal activity at least two-fold. Importantly, two novel molecules identified in the HTS increased proteasome activity more potently and more rapidly than the HDAC6-specific inhibitors Tubastatin-A and ACY-1215 (Ricolinostat) with comparatively low cytotoxicity. Proteasomes degrade chicken ovalbumin (Ova) to generate the immunodominant antigen SIINFEKL presented at the cell surface complexed with the MHC-class I molecule H-2Kb. Treatment of tumor cells with Tubastatin-A and ACY-1215 increased levels of the MHC-class I-SIINFEKL complex by ~3-fold. Tumor cells were pretreated with Tubastatin-A and ACY-1215 and then co-cultured with CTLs that had been genetically-engineered to express a SIINFEKL-restricted T-cell receptor (TCR). Pre-treatment of lymphoma or multiple myeloma cells with novel HDAC6 inhibitors also increased tumor lysis by CTLs that expressed the SIINFEKL-restricted TCR by 2-fold. Taken together, our results support repositioning pharmacologics that inhibit HDAC6 to activate proteasomal generation of antigenic peptides and boost antigen presentation as cancer immunotherapeutics.

Citation Format: Priyanka S. Rana, James Ignatz-Hoover, James J. Driscoll. Discovery of novel HDAC6 inhibitors that enhance proteasomal activity to boost antigen presentation and trigger anti-myeloma T-cell immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6235.
Supplementary Table 2 from Mutual Exclusivity Analysis of Genetic and Epigenetic Drivers in Melanoma Identifies a Link Between p14ARF and RARβ Signaling
Authors: Dahl Christina , Christensen Claus , Jönsson Göran , Lorentzen Anders , Skjødt Mette Louise , Borg Åke , Pawelec Graham , Guldberg Per
Published: April 2023

PDF file - 69K, Mutation details.
Supplementary Figure 2 from Procollagen Lysyl Hydroxylase 2 Is Essential for Hypoxia-Induced Breast Cancer Metastasis
Authors: Gilkes Daniele M. , Bajpai Saumendra , Wong Carmen C. , Chaturvedi Pallavi , Hubbi Maimon E. , Wirtz Denis , Semenza Gregg L.
Published: April 2023

PDF file - 135K, Figure S2. Efficiency of PLOD2 knockdown in MDA-MB-435 cells.
Supplementary Figure 1 from Bioactive Lipids S1P and C1P Are Prometastatic Factors in Human Rhabdomyosarcoma, and Their Tissue Levels Increase in Response to Radio/Chemotherapy
Authors: Schneider Gabriela , Bryndza Ewa , Abdel-Latif Ahmed , Ratajczak Janina , Maj Magdalena , Tarnowski Maciej , Klyachkin Yuri M. , Houghton Peter , Morris Andrew J. , Vater Axel , Klussmann Sven , Kucia Magdalena , Ratajczak Mariusz Z.
Published: April 2023

Supplementary Figure 1 - PDF file 39K, S1P and C1P activate MAPK and AKT in human RMS cell lines in G proteincoupled receptor-dependent manner
Supplementary Tables 1-3 from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality
Authors: Bluemn Eric G. , Spencer Elysia Sophie , Mecham Brigham , Gordon Ryan R. , Coleman Ilsa , Lewinshtein Daniel , Mostaghel Elahe , Zhang Xiaotun , Annis James , Grandori Carla , Porter Christopher , Nelson Peter S.
Published: April 2023

PDF, 101K, Supplementary Table 1: Tissue microarray clinical-pathological parameters. Supplementary Table 2: siRNA sequences. Supplementary Table 3: qRT-PCR primer sequences.
Supplemental Table 2 from A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function
Authors: Menezes Daniel L. , Holt Jenny , Tang Yan , Feng Jiajia , Barsanti Paul , Pan Yue , Ghoddusi Majid , Zhang Wei , Thomas George , Holash Jocelyn , Lees Emma , Taricani Lorena
Published: April 2023

Supplemental Table 2. SiRNA sequences (Supplemental data)
Supplemental Figure legends from A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function
Authors: Menezes Daniel L. , Holt Jenny , Tang Yan , Feng Jiajia , Barsanti Paul , Pan Yue , Ghoddusi Majid , Zhang Wei , Thomas George , Holash Jocelyn , Lees Emma , Taricani Lorena
Published: April 2023

Supplemental Figure legends. Supplemental Figure 1. Kinase selectivity profile of ATRi. Supplemental Figure 2. Screening of inhibitors in cellular γ-H2AX assay in U2OS cells. Supplemental Figure 3. Flow cytometry profiles assessing γ-H2AX response to compare antimetabolite combinations with a fixed concentration of ATRi in U2OS cells. Supplemental Figure 4. γ-H2AX response and cell viability following ATRi treatment in U2OS cells. Supplemental Figure 5. In vivo pharmacokinetics and γ-H2AX pharmacodynamics of ATRi in GRANTA-519 (ATM mut) MCL tumor xenograft model.
Supplemental Table 11 from Expression of ANRIL–Polycomb Complexes–CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value
Authors: Meseure Didier , Vacher Sophie , Alsibai Kinan Drak , Nicolas Andre , Chemlali Walid , Caly Martial , Lidereau Rosette , Pasmant Eric , Callens Celine , Bieche Ivan
Published: April 2023

Relationship between P16 transcripts levels and classical clinical biological parameters in a series of 456 breast cancers.
Supplemental Table 1 from Expression of ANRIL–Polycomb Complexes–CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value
Authors: Meseure Didier , Vacher Sophie , Alsibai Kinan Drak , Nicolas Andre , Chemlali Walid , Caly Martial , Lidereau Rosette , Pasmant Eric , Callens Celine , Bieche Ivan
Published: April 2023

Pathological and clinical characteristics of the 456 patients in relation to metastasis free survival (MFS)
Supplemental Figure 2 from Expression of ANRIL–Polycomb Complexes–CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value
Authors: Meseure Didier , Vacher Sophie , Alsibai Kinan Drak , Nicolas Andre , Chemlali Walid , Caly Martial , Lidereau Rosette , Pasmant Eric , Callens Celine , Bieche Ivan
Published: April 2023

Immunohistochemical staining for p15, p16, and p14.
Supplementary Figure 2 from miR-200c Targets CDK2 and Suppresses Tumorigenesis in Renal Cell Carcinoma
Authors: Wang Xuegang , Chen Xuanyu , Han Weiwei , Ruan Anming , Chen Li , Wang Rong , Xu Zhenghong , Xiao Pei , Lu Xing , Zhao Yan , Zhou Jia , Chen Shaoyong , Du Quansheng , Yang Hongmei , Zhang Xiaoping
Published: April 2023

Supplementary Figure 2. CDK2 mRNA expressed in cell lines and tissues. (A) Expression level of CDK2 mRNA in SN12-PM6 and 786-O cells with or without overexpressing miR-200c. (B) Expression level of CDK2 mRNA in 30 paired ccRCC and its normal tissues.
Supplemental Figure 1 from Expression of ANRIL–Polycomb Complexes–CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value
Authors: Meseure Didier , Vacher Sophie , Alsibai Kinan Drak , Nicolas Andre , Chemlali Walid , Caly Martial , Lidereau Rosette , Pasmant Eric , Callens Celine , Bieche Ivan
Published: April 2023

The ANRIL pathway.
Supplementary Table 1 from Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal
Authors: Morris Van , Rao Xiayu , Pickering Curtis , Foo Wai Chin , Rashid Asif , Eterovic Karina , Kim Taebeom , Chen Ken , Wang Jing , Shaw Kenna , Eng Cathy
Published: April 2023

Analyzed genes on the 263 gene panel.
Supplementary Figure Legends from FAK Inhibition Abrogates the Malignant Phenotype in Aggressive Pediatric Renal Tumors
Authors: Megison Michael L. , Gillory Lauren A. , Stewart Jerry E. , Nabers Hugh C. , Mrozcek-Musulman Elizabeth , Beierle Elizabeth A.
Published: April 2023

PDF file - 55KB
Supplementary Figure 2C from Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal
Authors: Morris Van , Rao Xiayu , Pickering Curtis , Foo Wai Chin , Rashid Asif , Eterovic Karina , Kim Taebeom , Chen Ken , Wang Jing , Shaw Kenna , Eng Cathy
Published: April 2023

MLL3 data.
Supplementary Figure 2B from Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal
Authors: Morris Van , Rao Xiayu , Pickering Curtis , Foo Wai Chin , Rashid Asif , Eterovic Karina , Kim Taebeom , Chen Ken , Wang Jing , Shaw Kenna , Eng Cathy
Published: April 2023

RRBP1 data.
Supplementary Figure 1 from FAK Inhibition Abrogates the Malignant Phenotype in Aggressive Pediatric Renal Tumors
Authors: Megison Michael L. , Gillory Lauren A. , Stewart Jerry E. , Nabers Hugh C. , Mrozcek-Musulman Elizabeth , Beierle Elizabeth A.
Published: April 2023

PDF file - 1930KB, Supplemental Data Figure S1. A., B. PF-573,228 (PF) and 1,2,4,5,-benzenetetraamine tetrahydrochloride (Y15) inhibition of FAK in SK-NEP-1 renal tumor cell lines. Immunoblotting for cleaved caspase 3 was utilized to further demonstrate apoptosis. SK-NEP-1 cells were treated with PF of Y15 for 24 hours and cell lysates collected. Immunoblotting showed increased cleaved caspase 3 following both PF (A) and Y15 (B) treatment in this cell line, indicating apoptosis. C. FAK inhibition with siRNA in G401 human renal tumor cell line. G401 cells were treated with negative control siRNA (siNeg) or siRNA specific for FAK (siFAK, 20, 40, 60 nM) for 24 hours. Immunoblotting for FAK showed decreased FAK expression in the G401 cells beginning with 20 nM siFAK. There was a decrease in the phosphorylation of kinases upstream and downstream from FAK including Jnk, Src and Erk 1/2 following FAK abrogation. Treatment with siFAK did not affect the phosphorylation of Akt kinase. Expression of total Jnk, Src, Akt and Erk 1/2 were not affected by inhibition of total FAK by siRNA. D., E. Combination treatment of PF-573,228 (PF) and 1,2,4,5,-benzenetetraamine tetrahydrochloride (Y15) for inhibition of FAK in human renal tumor cell lines. G401 and SK-NEP-1 cells were treated with PF and Y15 alone or in combination for 24 hours. AlamarBlue assay was used to measure cell viability. Using the method of Chou 26 the combination indices (CI) were calculated and isobolograms constructed. The straight line connects the LD50 of each small molecule when administered alone. CI values (calculated using the LD50 of the molecules when utilized together) falling above this line suggest and antagonistic effect, those below the line a synergistic effect, and those on the line are thought to represent an additive effect. D. In the G401 cell line the CI values were 0.88 and 0.82. E. For the SK-NEP-1 cell line the CI values were 0.98 and 0.94. These values were close to 1 suggesting that the effect of using both PF and Y15 was an additive one.
Supplementary Figure 2A from Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal
Authors: Morris Van , Rao Xiayu , Pickering Curtis , Foo Wai Chin , Rashid Asif , Eterovic Karina , Kim Taebeom , Chen Ken , Wang Jing , Shaw Kenna , Eng Cathy
Published: April 2023

PIK3CA data.
Supplementary Data from Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK
Authors: Toste Paul A. , Nguyen Andrew H. , Kadera Brian E. , Duong Mindy , Wu Nanping , Gawlas Irmina , Tran Linh M. , Bikhchandani Mihir , Li Luyi , Patel Sanjeet G. , Dawson David W. , Donahue Timothy R.
Published: April 2023

Figures S1-4 and Table S1 Figure S1. N-CAFs and R-CAFs were exposed to the indicated concentrations of gemcitabine for 72h, and viability was measured via MTT assay. 3 biologic replicates were included in the experiment. **p{less than or equal to}0.01, **** p{less than or equal to}0.0001 Figure S2. MiaPaCa-2 cells (1 X 105) were subcutaneously injected with N-CAF cells expressing GFP (3 X 105) in NSG mice. At 6 weeks, tumors were harvested and fluorescence microscopy was performed. Representative images of H&E stained sections as well as fluorescence microscopy are displayed. Only occasional GFP+ CAFs were present after 6 weeks. Figure S3. Primary CAFs were treated with 1µM gemcitabine plus DMSO or the above listed small molecule inhibitors for 96h and SASP mediator expression was compared to untreated cells via qRT-PCR. Because of limited primary cell numbers, the experiment was performed once in multiple cell lines rather than being replicated in any single line. Drug concentrations and targets: SB203580 10µM- p38 MAPK, SP600125 20µM- JNK, BEZ235 1µM- ATM/ATR/DNA-PK/PI3K/mTOR, AZD77622 200nM- Chk1/Chk2, VE821 2µM- ATR, KU55933 20µM- ATM. Figure S4. Combined data from Figure S3. The mean normalized expression of each marker from CAF1-3 is displayed. In this combined analysis, none of the changes reached statistical significance.
Supplementary Data from Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications
Authors: Lazo de la Vega Lorena , McHugh Jonathan B. , Cani Andi K. , Kunder Komal , Walocko Frances M. , Liu Chia-Jen , Hovelson Daniel H. , Robinson Dan , Chinnaiyan Arul M. , Tomlins Scott A. , Harms Paul W.
Published: April 2023

Figure S1. (A) Overexpression of p53 in olfactory neuroblastoma tumor harboring an inactivating TP53 mutation. (B) Representative example of p53 expression in olfactory neuroblastoma tumor lacking TP53 mutation. Immunohistochemistry, 400x magnification. figure S2. (A) Nuclear localization of beta catenin in olfactory neuroblastoma tumor harboring an activating CTNNB1 mutation. (B) Representative example of membranous beta catenin expression in olfactory neuroblastoma tumor lacking CTNNB1 mutation. Immunohistochemistry, 400x magnification. Table S1: Immunohistochemistry protocols Table S2: Clinicopathologic features of olfactory neuroblastoma cohort Table S3: DNA sequencing statistics for profiled olfactory neuroblastoma samples Table S4: Prioritized somatic nonsynonymous mutations in olfactory neuroblastoma cases identified by next generation sequencing Table S5: FGFR3 copy number in olfactory neuroblastomas by next generation sequencing Table S6. Targeted multiplexed PCR based RNA sequencing statistics for ONB samples
Supplementary Figure 1 from DNA Damage Induces a Secretory Program in the Quiescent TME that Fosters Adverse Cancer Phenotypes
Authors: Gomez-Sarosi Luis , Sun Yu , Coleman Ilsa , Bianchi-Frias Daniella , Nelson Peter S.
Published: April 2023

Pathway enrichment of quiescent fibroblasts.
Figure S6 from miR-652 Promotes Tumor Proliferation and Metastasis by Targeting RORA in Endometrial Cancer
Authors: Sun Xiaomei , Dongol Samina , Qiu Chunping , Xu Ying , Sun Chenggong , Zhang Zhiwei , Yang Xingsheng , Zhang Qing , Kong Beihua
Published: April 2023

MiR-652 promotes tumor proliferation and metastasis via miR-652/RORA/β-catenin pathway
Figure S5 from miR-652 Promotes Tumor Proliferation and Metastasis by Targeting RORA in Endometrial Cancer
Authors: Sun Xiaomei , Dongol Samina , Qiu Chunping , Xu Ying , Sun Chenggong , Zhang Zhiwei , Yang Xingsheng , Zhang Qing , Kong Beihua
Published: April 2023

RORA is negatively correlated with the expression of miR-652 independent of menstrual cycle
Figure S4 from miR-652 Promotes Tumor Proliferation and Metastasis by Targeting RORA in Endometrial Cancer
Authors: Sun Xiaomei , Dongol Samina , Qiu Chunping , Xu Ying , Sun Chenggong , Zhang Zhiwei , Yang Xingsheng , Zhang Qing , Kong Beihua
Published: April 2023

Morphological changes in miR-652 overexpressed cells compared to control cells
Figure S2 from miR-652 Promotes Tumor Proliferation and Metastasis by Targeting RORA in Endometrial Cancer
Authors: Sun Xiaomei , Dongol Samina , Qiu Chunping , Xu Ying , Sun Chenggong , Zhang Zhiwei , Yang Xingsheng , Zhang Qing , Kong Beihua
Published: April 2023

Expression level of miR-652 in transfected EC cell lines
Figure S4 from CHCHD2 Is Coamplified with EGFR in NSCLC and Regulates Mitochondrial Function and Cell Migration
Authors: Wei Yuhong , Vellanki Ravi N. , Coyaud Étienne , Ignatchenko Vladimir , Li Lei , Krieger Jonathan R. , Taylor Paul , Tong Jiefei , Pham Nhu-An , Liu Geoffrey , Raught Brian , Wouters Bradly G. , Kislinger Thomas , Tsao Ming Sound , Moran Michael F.
Published: April 2023

Figure S4. Localization of endogenous CHCHD2 and CHCHD2-Flag, and proteins identified by AP-MS
Figure S3 from CHCHD2 Is Coamplified with EGFR in NSCLC and Regulates Mitochondrial Function and Cell Migration
Authors: Wei Yuhong , Vellanki Ravi N. , Coyaud Étienne , Ignatchenko Vladimir , Li Lei , Krieger Jonathan R. , Taylor Paul , Tong Jiefei , Pham Nhu-An , Liu Geoffrey , Raught Brian , Wouters Bradly G. , Kislinger Thomas , Tsao Ming Sound , Moran Michael F.
Published: April 2023

Figure S3. NSCLC cell proteome analysis
Supplementary materials, methods, and figures 1-4 from Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition–Associated Checkpoint Abrogation
Authors: Mikami K. , Medová M. , Nisa L. , Francica P. , Glück A.A. , Tschan M.P. , Blaukat A. , Bladt F. , Aebersold D.M. , Zimmer Y.
Published: April 2023

Suppl. figure 1. Expression and activity of CHK2 in MET-dependent cell lines EBC-1 and GTL-16. CHK2 phosphorylation on Thr68 (p-CHK2) and total CHK2 levels were determined in EMD-1214063 (16 h), IR (30 min) or dually treated (16 h drug treatment prior to IR) EBC-1 and GTL-16 cells. β Actin was used as a loading control. Suppl. figure 2 A. XTT-based viability screen of MET-dependent cell lines treated with EMD- 1214063 (50 nM) for 96 h. B. Relative DNA-binding activity of p53 was determined in irradiated cells (3 h post-IR) and normalized to the protein concentration. C. The p21- promoter luciferase reporter assay was carried out in GTL-16 p53-knockdown cells after 4 h, 8 h and 24 h of IR (10 Gy) and compared to the wildtype p53 counterpart. The relative p21 promoter activity was normalized to the Renilla luciferase. Suppl. figure 3 A. Cell cycle distribution of GTl-16 shC and shp53 cells in selective CHK1 inihibitor CHIR-124 (30 nM), IR (10 Gy) and dually treated conditions (72 h post-IR, 1 h pretreatment with CHIR-124) displays significantly higher G2/M population in p53-knockdown in comparison with shC cells. B. Relative cytotoxicity was determined 96 h post-IR with or without CHIR-124 (30 nM, 1 h prior to IR), showing considerable induction of cell death in shp53. Suppl. figure 4 Representative images (upper panel) of viable and dead GTL-16 shp53 cells, calcium AM (green) or ethidium homodimer (EthD-1; red) positive, respectively, were acquired following EMD-1214063 (50 nM, 2 h pre-treatment prior IR), IR (10 Gy) and nocodazole (200 ng/ml, 2 h pre-treatment prior IR) or BI 2536 (100nM, 2 h pre-treatment prior IR) treatment 72 h after IR (LIVE/DEAD®). Inhibition of mitotic progression by nocodazole or Polo-like kinase 1 inhibitor BI 2536 compromised the cytotoxic effect of the combined EMD-1214063/IR treatment. (Quantification of dead (EthD-1-positive) cells is provided (lower panel)).
Supplementary Figure S2 from E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer
Authors: Cheng Chao , Varn Frederick S. , Marsit Carmen J.
Published: April 2023

The survival curves of E2F4>0 and E2F4<0 groups are compared in (A) NMIBC, (B) MIBC, (C) grade G1, and (D) grade G1 NMIBC samples. This figure is similar to Figure 4, but all patients with or without systemic chemotherapy treatment are included.
Supplementary Tables 1 - 5 from PP6C Hotspot Mutations in Melanoma Display Sensitivity to Aurora Kinase Inhibition
Authors: Gold Heidi L. , Wengrod Jordan , de Miera Eleazar Vega-Saenz , Wang Ding , Fleming Nathaniel , Sikkema Lisa , Kirchhoff Tomas , Hochman Tsivia , Goldberg Judith D. , Osman Iman , Gardner Lawrence B.
Published: April 2023

PDF file - 151K, Supplemental Table 1. mutations found in NYU cohort and previously discovered by Hodis et al; and Krauthammer et al; Supplemental Table 2. Breslow-Day test of homogeneity for association between PP6C, BRAF, or NRAS mutations in Primary and Metastatic patients respectively. Supplemental Table 3. Bbaseline characteristics and prognostic factors by PP6C mutation status in primary and metastatic patients. Supplemental Table 4: PP6C, BRAF and NRAS mutation allele:wild-type allele ratios. Supplemental Table 5. Correlation of PP6R binding and Aurora A Kinase phosphorylation(primary patients only).
Supplementary Table 2 from BRAFV600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation
Authors: Silva Jillian M. , Bulman Christina , McMahon Martin
Published: April 2023

PDF file - 62K, Supplementary Table S2. Pharmacological agents targeted to the ERK1/2 MAP kinase or PI3'- kinase-AKT pathways.
Supplemental Figure Legends from The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis
Authors: Vetter Nancy S. , Kolb E.A. , Mills Christopher C. , Sampson Valerie B.
Published: April 2023

Legends for Figure S1 and Figure S2
Figure S2 from The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis
Authors: Vetter Nancy S. , Kolb E.A. , Mills Christopher C. , Sampson Valerie B.
Published: April 2023

HOS and U2OS cells were transfected with miR-34a and Cyclin D1 and p27 protein expression were determined by immunoblot.
Supplementary Figure 3 from BRAFV600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation
Authors: Silva Jillian M. , Bulman Christina , McMahon Martin
Published: April 2023

PDF file - 117K, Supplementary Fig. S3. Effects of rapamycin on melanoma cell signaling and proliferation.
Supplementary Figure 2 from BRAFV600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation
Authors: Silva Jillian M. , Bulman Christina , McMahon Martin
Published: April 2023

PDF file - 64K, Supplementary Fig. S2. Protein quantification of p70S6K, rpS6, and 4E-BP1 phosphorylation.
Supplementary Figure 1 from BRAFV600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation
Authors: Silva Jillian M. , Bulman Christina , McMahon Martin
Published: April 2023

PDF file - 74K, Supplementary Fig. S1. A schematic diagram of the ERK1/2 MAP kinase and PI3'-kinase-AKT signaling pathways and the targeted pharmacological inhibitors used in this study.
Supplementary Figure 3 from Fhit Regulates EMT Targets through an EGFR/Src/ERK/Slug Signaling Axis in Human Bronchial Cells
Authors: Joannes Audrey , Grelet Simon , Duca Laurent , Gilles Christine , Kileztky Claire , Dalstein Véronique , Birembaut Philippe , Polette Myriam , Nawrocki-Raby Béatrice
Published: April 2023

PDF file - 112KB, Supplementary figure 3: Quantifications of Western blot and zymography analyses. The levels of Slug, vimentin and MMP-9 in scrambled or Fhit siRNA HBE4-E6/E7 transfectants were quantified either after co-transfection with Slug siRNA 1 (a) or Slug siRNA 2 (b) or in the presence of PD98059 (c), PP1 (d), Gefitinib (e) and anti-EGFR antibody (f). Western blot quantifications are provided for each target gene normalized to GAPDH. Data are expressed as fold induction relative to the respective controls. *P < 0.05; **P < 0.01; ***P < 0.001.
Supplementary Figures 1 - 9 from Angiopoietin-like Protein 2 Accelerates Carcinogenesis by Activating Chronic Inflammation and Oxidative Stress
Authors: Aoi Jun , Endo Motoyoshi , Kadomatsu Tsuyoshi , Miyata Keishi , Ogata Aki , Horiguchi Haruki , Odagiri Haruki , Masuda Tetsuro , Fukushima Satoshi , Jinnin Masatoshi , Hirakawa Satoshi , Sawa Tomohiro , Akaike Takaaki , Ihn Hironobu , Oike Yuichi
Published: April 2023

PDF file - 1314K, Supp Fig 1. Oxidative stress-dependent formation of 4-HNE and HNE-modified proteins. Supp Fig 2. NAC treatment decreases susceptibility of wild-type mice to chemical skin carcinogenesis. Supp Fig 3. Chemical treatment of Angptl2 KO mice does not alter Msh2 expression. Supp Fig 4. Levels of various DNA repair proteins in skin of wild-type versus K14-Angptl2 Tg mice. Supp Fig 5. Levels of various DNA repair proteins in skin of wild-type versus Angptl2 KO mice. Supp Fig 6. Levels of various DNA repair proteins in skin of Angptl2 Tg mice with or without NAC treatment. Supp Fig 7. Msh2 expression is ameliorated by antioxidant treatment of chemically-treated wild-type mice. Supp Fig 8. MSH levels are inversely correlated with ANGPTL2 expression in human tissues exhibiting actinic keratosis. Supp Fig 9. Mechanistic model of carcinogenesis accelerated by Angptl2.
Supplementary Figure 2 from Fhit Regulates EMT Targets through an EGFR/Src/ERK/Slug Signaling Axis in Human Bronchial Cells
Authors: Joannes Audrey , Grelet Simon , Duca Laurent , Gilles Christine , Kileztky Claire , Dalstein Véronique , Birembaut Philippe , Polette Myriam , Nawrocki-Raby Béatrice
Published: April 2023

PDF file - 297KB, Supplementary figure 2: Representative fields of cell invasion assays. The invasive capacities of scrambled or Fhit siRNA HBE4-E6/E7 transfectants were tested in a modified Boyden chamber invasion assay either after co-transfection with Slug siRNA 1 (a) or Slug siRNA 2 (b) or in the presence of PD98059 (c), PP1 (d), Gefitinib (e) and anti-EGFR antibody (f). The respective controls for Slug siRNA, inhibitor and neutralizing antibody experiments were scrambled siRNA, DMSO and IgG1. Bar = 100 ?m.
Data Supplement from DRO1 Inactivation Drives Colorectal Carcinogenesis in ApcMin/+ Mice
Authors: Grill Jessica I. , Neumann Jens , Herbst Andreas , Hiltwein Felix , Ofner Andrea , Marschall Maximilian K. , Wolf Eckhard , Kirchner Thomas , Göke Burkhard , Schneider Marlon R. , Kolligs Frank T.
Published: April 2023

Supplementary Figure S1. Genetic deletion of Dro1. Supplementary Figure S2. Loss of DRO1 has no effect on intestinal anatomy and distribution of the four cell lineages along the crypt-villus-axis. Supplementary Figure S3. Loss of DRO1 has no effect on the rate of proliferation and apoptosis in the intestinal epithelium. Supplementary Figure S4. Small intestinal and colonic adenomas in Dro1-/-;ApcMin/+ mice are histologically similar to Dro1+/+;ApcMin/+ adenomas. Supplementary Figure S5. Loss of DRO1 leads to the enhanced formation of adenoma and adenocarcinomas in the colon of 10-week-old ApcMin/+ mice. Supplementary Figure S6. DRO1 deficiency has no effect on the formation of aberrant crypt foci in the colon of ApcMin/+ mice. Supplementary Figure S7. Loss of DRO1 has no effect on tissue architecture and the rate of proliferation and apoptosis in the colon of 5-week-old ApcMin/+ mice. At this age both groups were free of colonic polyps. Supplementary Figure S8. Loss of DRO1 has no effect on Wnt signaling activation and the rate of apoptosis in polyps from ApcMin/+ mice. Supplementary Figure S9. DRO1 expression is reduced in the majority of colorectal carcinomas. Supplementary Figure S10. DRO1 deficiency leads to increased phosphorylation of ERK1/2 and upregulation of c-MYC in colon tumors from ApcMin/+ mice. Supplementary Table S1. Primer sequences. Supplementary Table S2. Reagents used for immunohistochemistry. Supplementary Table S3. Loss of DRO1 leads to the enhanced formation of adenoma and adenocarcinomas in the colon of 10-week-old ApcMin/+ mice.
Supplementary Figure Legends from Contribution of Tumor Heterogeneity in a New Animal Model of CNS Tumors
Authors: Chen Fuyi , Becker Albert J. , LoTurco Joseph J.
Published: April 2023

PDF file - 117K
Supplementary Figure 6 from Contribution of Tumor Heterogeneity in a New Animal Model of CNS Tumors
Authors: Chen Fuyi , Becker Albert J. , LoTurco Joseph J.
Published: April 2023

PDF file - 1616K, Gene expression profile of ATRT like tumors.
Supplementary Fig. S8 from Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells
Authors: Lambert Arthur W. , Wong Chen Khuan , Ozturk Sait , Papageorgis Panagiotis , Raghunathan Rekha , Alekseyev Yuriy , Gower Adam C. , Reinhard Björn M. , Abdolmaleky Hamid M. , Thiagalingam Sam
Published: April 2023

POSTN regulates cancer stem cell phenotypes in Hs578T cells
Supplementary Figure 4 from Contribution of Tumor Heterogeneity in a New Animal Model of CNS Tumors
Authors: Chen Fuyi , Becker Albert J. , LoTurco Joseph J.
Published: April 2023

PDF file - 2064K, Additional immunohistopathological features of ATRT like tumor induced by PBCAG-NeuroD1 and PBCAG-HRasV12/AKT.
Supplementary Fig. S7 from Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells
Authors: Lambert Arthur W. , Wong Chen Khuan , Ozturk Sait , Papageorgis Panagiotis , Raghunathan Rekha , Alekseyev Yuriy , Gower Adam C. , Reinhard Björn M. , Abdolmaleky Hamid M. , Thiagalingam Sam
Published: April 2023

Conditioned media rescue of the ALDH subpopulation and inhibition of ERK signaling in SUM159 cells
Supplementary Fig. S5 from Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells
Authors: Lambert Arthur W. , Wong Chen Khuan , Ozturk Sait , Papageorgis Panagiotis , Raghunathan Rekha , Alekseyev Yuriy , Gower Adam C. , Reinhard Björn M. , Abdolmaleky Hamid M. , Thiagalingam Sam
Published: April 2023

Knockdown of POSTN in MIII cells impairs mammosphere formation
Supplementary Fig. S3 from Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells
Authors: Lambert Arthur W. , Wong Chen Khuan , Ozturk Sait , Papageorgis Panagiotis , Raghunathan Rekha , Alekseyev Yuriy , Gower Adam C. , Reinhard Björn M. , Abdolmaleky Hamid M. , Thiagalingam Sam
Published: April 2023

Knockdown of POSTN and ITGB3 in SUM159 cells
Supplementary Fig. S2 from Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells
Authors: Lambert Arthur W. , Wong Chen Khuan , Ozturk Sait , Papageorgis Panagiotis , Raghunathan Rekha , Alekseyev Yuriy , Gower Adam C. , Reinhard Björn M. , Abdolmaleky Hamid M. , Thiagalingam Sam
Published: April 2023

Co-expression of POSTN and integrin αvβ3 in basal-like breast cancer cell lines
Supplementary Table from Linking Cancer Metabolism to DNA Repair and Accelerated Senescence
Authors: Efimova Elena V. , Takahashi Satoe , Shamsi Noumaan A. , Wu Ding , Labay Edwardine , Ulanovskaya Olesya A. , Weichselbaum Ralph R. , Kozmin Sergey A. , Kron Stephen J.
Published: April 2023

Small molecules used in this study.
Supplementary Figure Legends from Linking Cancer Metabolism to DNA Repair and Accelerated Senescence
Authors: Efimova Elena V. , Takahashi Satoe , Shamsi Noumaan A. , Wu Ding , Labay Edwardine , Ulanovskaya Olesya A. , Weichselbaum Ralph R. , Kozmin Sergey A. , Kron Stephen J.
Published: April 2023

Supplementary Figure Legends
Supplementary Movie 3 from O-GlcNAcylation Enhances Double-Strand Break Repair, Promotes Cancer Cell Proliferation, and Prevents Therapy-Induced Senescence in Irradiated Tumors
Authors: Efimova Elena V. , Appelbe Oliver K. , Ricco Natalia , Lee Steve S.-Y. , Liu Yue , Wolfgeher Donald J. , Collins Tamica N. , Flor Amy C. , Ramamurthy Aishwarya , Warrington Sara , Bindokas Vytautas P. , Kron Stephen J.
Published: April 2023

Intratumoral IRIF imaging demonstrates similar patterns for GFP-IBD (green) and TagRFP-IBD (red) foci in tumor at 24 h after irradiation with 6 Gy
Supplementary Movie 1 from O-GlcNAcylation Enhances Double-Strand Break Repair, Promotes Cancer Cell Proliferation, and Prevents Therapy-Induced Senescence in Irradiated Tumors
Authors: Efimova Elena V. , Appelbe Oliver K. , Ricco Natalia , Lee Steve S.-Y. , Liu Yue , Wolfgeher Donald J. , Collins Tamica N. , Flor Amy C. , Ramamurthy Aishwarya , Warrington Sara , Bindokas Vytautas P. , Kron Stephen J.
Published: April 2023

intratumoral imaging of Hoechst 33342 stained nuclei (blue), GFP-IBD (green) and TagRFP-IBD (red) reporters in untreated control tumor xenograft.
Supplementary Methods and Supplementary Figure Legends from O-GlcNAcylation Enhances Double-Strand Break Repair, Promotes Cancer Cell Proliferation, and Prevents Therapy-Induced Senescence in Irradiated Tumors
Authors: Efimova Elena V. , Appelbe Oliver K. , Ricco Natalia , Lee Steve S.-Y. , Liu Yue , Wolfgeher Donald J. , Collins Tamica N. , Flor Amy C. , Ramamurthy Aishwarya , Warrington Sara , Bindokas Vytautas P. , Kron Stephen J.
Published: April 2023

Supplementary Methods and Supplementary Figure, Movie and Table Legends
Figure legends text file from Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814
Authors: Sun Qing , Guo Yige , Liu Xiaohong , Czauderna Frank , Carr Michael I. , Zenke Frank T. , Blaukat Andree , Vassilev Lyubomir T.
Published: April 2023

Text file with figure legends and two references cited in Fig S6 legend
Supplementary Figures 1 - 6 from Identification of Cdk1–LATS–Pin1 as a Novel Signaling Axis in Anti-tubulin Drug Response of Cancer Cells
Authors: Yeung Benjamin , Khanal Prem , Mehta Virja , Trinkle-Mulcahy Laura , Yang Xiaolong
Published: April 2023

Supplementary Figure 1. Expression of LATS1 after anti-tubulin treatments. Supplementary Figure 2. Phosphorylation of LATS2 after anti-tubulin treatments in various cell lines. Supplementary Figure 3. Phosphorylation of LATS1 by Cdk1/Cyclin B in vitro. Supplementary Figure 4. Trypan blue exclusion analysis for cell death of HeLa cells transfected with different isomerases and treated with Taxol. Supplementary Figure 5. Suppression of transformation by LATS2 and its phosphorylation mutant. Supplementary Figure 6. In vitro phosphorylation of Pin1 and its deletions by LATS2.
Supplementary Figure 2 from Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis
Authors: de Queiroz Nina Marí Gual Pimenta , Xia Tianli , Konno Hiroyasu , Barber Glen N.
Published: April 2023

Ovarian cells infected with HSV1 expressing luciferase (HSV-luc).
Supplementary Figure 5 from Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer
Authors: Nguyen Dan J.M. , Theodoropoulos George , Li Ying-Ying , Wu Chunjing , Sha Wei , Feun Lynn G. , Lampidis Theodore J. , Savaraj Niramol , Wangpaichitr Medhi
Published: April 2023

Survival probabilities of NSCLC patients with IDO1 expression.
Supplementary Figure 2 from Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer
Authors: Nguyen Dan J.M. , Theodoropoulos George , Li Ying-Ying , Wu Chunjing , Sha Wei , Feun Lynn G. , Lampidis Theodore J. , Savaraj Niramol , Wangpaichitr Medhi
Published: April 2023

Relative mRNA levels of CYP1B1.
Supplementary Materials and Methods from Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells
Authors: Graham Mindy K. , Kim Jiyoung , Da Joseph , Brosnan-Cashman Jacqueline A. , Rizzo Anthony , Baena Del Valle Javier A. , Chia Lionel , Rubenstein Michael , Davis Christine , Zheng Qizhi , Cope Leslie , Considine Michael , Haffner Michael C. , De Marzo Angelo M. , Meeker Alan K. , Heaphy Christopher M.
Published: April 2023

Supplementary Materials and Methods
Supplementary Figures 1-6 from Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells
Authors: Graham Mindy K. , Kim Jiyoung , Da Joseph , Brosnan-Cashman Jacqueline A. , Rizzo Anthony , Baena Del Valle Javier A. , Chia Lionel , Rubenstein Michael , Davis Christine , Zheng Qizhi , Cope Leslie , Considine Michael , Haffner Michael C. , De Marzo Angelo M. , Meeker Alan K. , Heaphy Christopher M.
Published: April 2023

Figure S1. LAPC-4 and CWR22RV1 are telomerase-positive ALT-negative cell lines. Figure S2. ATRXKOs were generated in LAPC-4 and CWR22Rv1 cells. Figure S3. Representative telomere restriction fragment (TRF) southern blots and signal intensity traces. Figure S4. TERT and TERC expression levels. Figure S5. CRISPR cas9 genome editing strategies targeting the TERC locus. Figure S6. RT-qPCR validation of genes differentially expressed in microarray.
Supplementary Figure 8 from The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
Authors: Braadland Peder R. , Ramberg Håkon , Grytli Helene Hartvedt , Urbanucci Alfonso , Nielsen Heidi Kristin , Guldvik Ingrid Jenny , Engedal Andreas , Ketola Kirsi , Wang Wanzhong , Svindland Aud , Mills Ian G. , Bjartell Anders , Taskén Kristin Austlid
Published: April 2023

Cell growth 2D and 3D
Supplementary Figure 7 from The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
Authors: Braadland Peder R. , Ramberg Håkon , Grytli Helene Hartvedt , Urbanucci Alfonso , Nielsen Heidi Kristin , Guldvik Ingrid Jenny , Engedal Andreas , Ketola Kirsi , Wang Wanzhong , Svindland Aud , Mills Ian G. , Bjartell Anders , Taskén Kristin Austlid
Published: April 2023

Publically available data sets
Supplementary Figure 6 from The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
Authors: Braadland Peder R. , Ramberg Håkon , Grytli Helene Hartvedt , Urbanucci Alfonso , Nielsen Heidi Kristin , Guldvik Ingrid Jenny , Engedal Andreas , Ketola Kirsi , Wang Wanzhong , Svindland Aud , Mills Ian G. , Bjartell Anders , Taskén Kristin Austlid
Published: April 2023

Publically available data sets
Supplemental table 2 from USP28 Deficiency Promotes Breast and Liver Carcinogenesis as well as Tumor Angiogenesis in a HIF-independent Manner
Authors: Richter Kati , Paakkola Teija , Mennerich Daniela , Kubaichuk Kateryna , Konzack Anja , Ali-Kippari Heidi , Kozlova Nina , Koivunen Peppi , Haapasaari Kirsi-Maria , Jukkola-Vuorinen Arja , Teppo Hanna-Riikka , Dimova Elitsa Y. , Bloigu Risto , Szabo Zoltan , Kerkelä Risto , Kietzmann Thomas
Published: April 2023

Overview of macroscopic changes in liver morphology.
Supplemental table 1 from USP28 Deficiency Promotes Breast and Liver Carcinogenesis as well as Tumor Angiogenesis in a HIF-independent Manner
Authors: Richter Kati , Paakkola Teija , Mennerich Daniela , Kubaichuk Kateryna , Konzack Anja , Ali-Kippari Heidi , Kozlova Nina , Koivunen Peppi , Haapasaari Kirsi-Maria , Jukkola-Vuorinen Arja , Teppo Hanna-Riikka , Dimova Elitsa Y. , Bloigu Risto , Szabo Zoltan , Kerkelä Risto , Kietzmann Thomas
Published: April 2023

Primers used for qRT-PCR
Supplementary Figure 3 from The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
Authors: Braadland Peder R. , Ramberg Håkon , Grytli Helene Hartvedt , Urbanucci Alfonso , Nielsen Heidi Kristin , Guldvik Ingrid Jenny , Engedal Andreas , Ketola Kirsi , Wang Wanzhong , Svindland Aud , Mills Ian G. , Bjartell Anders , Taskén Kristin Austlid
Published: April 2023

Therapy resistance shADRB2 cell lines
Figure S4 from USP28 Deficiency Promotes Breast and Liver Carcinogenesis as well as Tumor Angiogenesis in a HIF-independent Manner
Authors: Richter Kati , Paakkola Teija , Mennerich Daniela , Kubaichuk Kateryna , Konzack Anja , Ali-Kippari Heidi , Kozlova Nina , Koivunen Peppi , Haapasaari Kirsi-Maria , Jukkola-Vuorinen Arja , Teppo Hanna-Riikka , Dimova Elitsa Y. , Bloigu Risto , Szabo Zoltan , Kerkelä Risto , Kietzmann Thomas
Published: April 2023

Knockdown of USP28 downregulates HIF-1a, c-Myc, c-Jun and Notch1 protein levels but enhances cell proliferation in MCF7 cells.
Figure S3 from USP28 Deficiency Promotes Breast and Liver Carcinogenesis as well as Tumor Angiogenesis in a HIF-independent Manner
Authors: Richter Kati , Paakkola Teija , Mennerich Daniela , Kubaichuk Kateryna , Konzack Anja , Ali-Kippari Heidi , Kozlova Nina , Koivunen Peppi , Haapasaari Kirsi-Maria , Jukkola-Vuorinen Arja , Teppo Hanna-Riikka , Dimova Elitsa Y. , Bloigu Risto , Szabo Zoltan , Kerkelä Risto , Kietzmann Thomas
Published: April 2023

Knockdown of USP28 affects HIF-1a, c-Myc, c-Jun and Notch1 protein levels and enhances EMT markers in BT-549 cells.
Figure S2 from USP28 Deficiency Promotes Breast and Liver Carcinogenesis as well as Tumor Angiogenesis in a HIF-independent Manner
Authors: Richter Kati , Paakkola Teija , Mennerich Daniela , Kubaichuk Kateryna , Konzack Anja , Ali-Kippari Heidi , Kozlova Nina , Koivunen Peppi , Haapasaari Kirsi-Maria , Jukkola-Vuorinen Arja , Teppo Hanna-Riikka , Dimova Elitsa Y. , Bloigu Risto , Szabo Zoltan , Kerkelä Risto , Kietzmann Thomas
Published: April 2023

Lack of USP28 does not affect p53 and 53BP1 protein levels in human cells or mouse tissue samples.
Figure S1 from USP28 Deficiency Promotes Breast and Liver Carcinogenesis as well as Tumor Angiogenesis in a HIF-independent Manner
Authors: Richter Kati , Paakkola Teija , Mennerich Daniela , Kubaichuk Kateryna , Konzack Anja , Ali-Kippari Heidi , Kozlova Nina , Koivunen Peppi , Haapasaari Kirsi-Maria , Jukkola-Vuorinen Arja , Teppo Hanna-Riikka , Dimova Elitsa Y. , Bloigu Risto , Szabo Zoltan , Kerkelä Risto , Kietzmann Thomas
Published: April 2023

USP28 expression in hepatocellular carcinoma and generation of an Usp28 knockout mouse.
Supplementary Data from The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
Authors: Braadland Peder R. , Ramberg Håkon , Grytli Helene Hartvedt , Urbanucci Alfonso , Nielsen Heidi Kristin , Guldvik Ingrid Jenny , Engedal Andreas , Ketola Kirsi , Wang Wanzhong , Svindland Aud , Mills Ian G. , Bjartell Anders , Taskén Kristin Austlid
Published: April 2023

Supplementary Material and Methods, Supplementary Figure Legends, Supplementary Tables
Table S4: Acetylated lysines on aromatase peptides identified by LC-MS/MS analysis in MCF-7 cells. from Aromatase Acetylation Patterns and Altered Activity in Response to Sirtuin Inhibition
Authors: Molehin Deborah , Castro-Piedras Isabel , Sharma Monica , Sennoune Souad R. , Arena Daphne , Manna Pulak R. , Pruitt Kevin
Published: April 2023

Supplementary Table 4: Detailed LC-MS/MS data of acetylated aromatase protein. Table showing the location of basally (clear) and SIRT-1 inhibitor IV induced (highlighted) acetylation of aromatase peptides from MCF-7 cells under conventional (20% O2) and physiological oxygen (2.5% O2) conditions.
Figure S1 from Epigenetic Reprogramming of Pericentromeric Satellite DNA in Premalignant and Malignant Lesions
Authors: Brückmann Nadine Heidi , Pedersen Christina Bøg , Ditzel Henrik Jørn , Gjerstorff Morten Frier
Published: April 2023

Staining of BMI1 in normal human tissues
Table S1: Primer sets used for cloning of N and C-V5 aromatase mutants from Aromatase Acetylation Patterns and Altered Activity in Response to Sirtuin Inhibition
Authors: Molehin Deborah , Castro-Piedras Isabel , Sharma Monica , Sennoune Souad R. , Arena Daphne , Manna Pulak R. , Pruitt Kevin
Published: April 2023

Supplementary Table 1: Primer sets used in cloning of aromatase into pcDNA3.1+ and those used to amplify V5-tagged aromatase in a pool of RNA and their expected DNA product size.
Figure S3 from Aromatase Acetylation Patterns and Altered Activity in Response to Sirtuin Inhibition
Authors: Molehin Deborah , Castro-Piedras Isabel , Sharma Monica , Sennoune Souad R. , Arena Daphne , Manna Pulak R. , Pruitt Kevin
Published: April 2023

V5-tagged aromatase protein colocalizes with endoplasmic reticulum marker calnexin in stably transfected HEK293 cells.
Supplementary Fig. S1-S4, Table S1 from Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging
Authors: Randall Elizabeth C. , Zadra Giorgia , Chetta Paolo , Lopez Begona G.C. , Syamala Sudeepa , Basu Sankha S. , Agar Jeffrey N. , Loda Massimo , Tempany Clare M. , Fennessy Fiona M. , Agar Nathalie Y.R.
Published: April 2023

S1. Segmentation map of a subset of lower Gleason tissue specimens, demonstrates regional differences between tumor and normal tissue, and between the two different Gleason grades S2. Example MALDI ion images of 2 long chain acylcarnitine species S3. Annotated H&E and serial frozen sections of human prostate tissue S4. Scores plot from PLSDA multivariate analysis of LESA MS data from tumor and normal prostate tissue Table 1. Pathological description of specimens used for MALDI MSI, cases were staged according to AJCC TNM 8th edition